KYKOF - Kyowa Kirin expands license pact with Synaffix

• Kyowa Kirin ( OTCPK:KYKOF ) expands the license agreement with Synaffix, by adding one new ADC to a total of three ADC programs.
• Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target.
• The decisions are driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin's lead program that was built by using Synaffix ADC technology.
• Per the terms, triggers $5 million immediate payment to Synaffix and total potential payments for the first ADC program alone of up to $171m plus royalties on commercial sales.

For further details see: